What is Carboxybenzylpenicillin used for?

Carboxybenzylpenicillin is indicated for Bacterial urinary infection, Enterobacter Prostatitis, Enterococcus Prostatitis, Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection.

What development phase is Carboxybenzylpenicillin in?

Carboxybenzylpenicillin is FDA-approved (marketed).

What is the generic name of Carboxybenzylpenicillin?

CARBENICILLIN is the generic (nonproprietary) name of Carboxybenzylpenicillin.

Last reviewed 2026-04-20 · How we verify

Carboxybenzylpenicillin (CARBENICILLIN)

FDA-approved approved Small molecule Quality 40/100

Carbenicillin, a marketed antibiotic, holds a niche position in treating bacterial urinary infections, with a key composition patent expiring in 2028. Its mechanism of inhibiting bacterial cell wall synthesis provides a robust therapeutic effect, distinguishing it within the same class of drugs such as ampicillin and amoxicillin. The primary risk lies in the competitive landscape, where multiple off-patent generics like ampicillin and azlocillin are already available, potentially eroding market share.

At a glance

Generic name	CARBENICILLIN
Drug class	Penicillin-class Antibacterial
Target	Muscarinic acetylcholine receptor M1
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	1982

Approved indications

Bacterial urinary infection
Enterobacter Prostatitis
Enterococcus Prostatitis
Enterococcus Urinary Tract Infection
Escherichia coli urinary tract infection
Morganella Morganii Urinary Tract Infection
Prostatitis
Proteus Prostatitis
Proteus urinary tract infection
Providencia Urinary Tract Infection
Pseudomonas Aeruginosa Urinary Tract Infection
Urinary tract infectious disease

Common side effects

No common side effects on file.

Drug interactions

demeclocycline
doxycycline
gentamicin
minocycline
netilmicin
oxytetracycline
tetracycline
tobramycin

Key clinical trials

Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carboxybenzylpenicillin CI brief — competitive landscape report
Carboxybenzylpenicillin updates RSS · CI watch RSS